◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Kyowa Kirin Co., Ltd. (4151)
来自官方财务报表的收入、利润与现金流历史。
Healthcare · 华尔街（美国） · 最近更新： 2026-10-02
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis.
关键数据
- 市值: JPY 1.17 trillion
- 收入（截至 2025-12-31 财年）: JPY 496.8B
- 净利润: JPY 67.0B
- 毛利率: 74.2%
- 净利率: 13.5%
查看交互式图表与完整报表 →
估值模型 (DCF) →
年度利润表
| 利润表 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|
| 总收入 | JPY 496.8B | JPY 495.6B | JPY 442.2B | JPY 398.4B |
| 毛利 | JPY 368.9B | JPY 362.9B | JPY 331.0B | JPY 311.5B |
| 营业利润（EBIT） | JPY 102.3B | JPY 91.9B | JPY 95.8B | JPY 82.4B |
| 净利 | JPY 67.0B | JPY 59.9B | JPY 81.2B | JPY 53.6B |
来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。
资产负债表、现金流、季度数据与完整财务比率见 4151 交互式查看器。 /companies/us/4151
类似公司
本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。
About TickerBase · Data methodology & sources · Privacy · Terms
TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.